Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have been assigned an average recommendation of “Hold” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $41.33.
OMCL has been the topic of several recent research reports. JPMorgan Chase & Co. increased their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Bank of America raised their price objective on Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Saturday. Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Finally, Wells Fargo & Company boosted their price objective on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th.
Check Out Our Latest Research Report on OMCL
Institutional Trading of Omnicell
Omnicell Stock Performance
OMCL stock opened at $40.47 on Tuesday. Omnicell has a 1-year low of $25.12 and a 1-year high of $45.84. The business has a 50-day moving average price of $43.22 and a 200 day moving average price of $34.42. The company has a market capitalization of $1.86 billion, a P/E ratio of -87.98, a PEG ratio of 47.11 and a beta of 0.83. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22.
Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. During the same quarter in the previous year, the business posted $0.29 EPS. The company’s quarterly revenue was down 7.4% compared to the same quarter last year. As a group, equities research analysts forecast that Omnicell will post 0.64 EPS for the current fiscal year.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Featured Stories
- Five stocks we like better than Omnicell
- Canadian Penny Stocks: Can They Make You Rich?
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.